Jeanne Bolger
Biography
Jeanne has over 35 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD) and Venture Investments. She spent 11 years in Licensing and Acquisition (L&A), including Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, and before that as Director in the Business Development group at GlaxoSmithKline.
Jeanne spent nearly 10 years (2012-2022) as Vice President Venture Investment in J&J’s corporate venture fund, Johnson & Johnson Innovation – JJDC. During that period, she was based in London, leading investments across Europe in start-up and early stage life science companies in areas of strategic interest to J&J’s business sectors in Pharmaceuticals and Biotechnology, Medical Devices and Consumer. She represented JJDC on the Board of Directors of over a dozen companies, including Aelix Therapeutics, Asceneuron SA, Aviado Bio, Biocartis, Calypso Biotech, Inivata, Merus, Pulmocide, S-Biomedic, Syndesi, T-Rex. Dr Bolger also represented JJDC’s LP investments in multiple Venture Capital Funds in UK and Europe as well as representing J&J’s interests in other funding vehicles including incubators and accelerators.
Education
Jeanne received her medical degree from University College Dublin. She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine at Trinity College Dublin. Jeanne sits on the Industry Advisory Board of CURAM, the SFI-funded Centre of Excellence charged with designing the next generation of smart medical devices, and on the Advisory Group of the National Health Innovation Hub which focuses on digital innovation in healthcare. She is on the Advisory Board of the Sir Francis Crick Translational Fund (UK), Chair of Board of Directors at Exevir SA (Private, Belgium) and Non-executive Director at Life Healthcare Group Holdings (JSE:LHC).
Why I enjoy working with Seroba?
Having worked over the years with different Seroba team members, I was delighted to join them as Venture Partner upon my retirement from Corporate venture investing. The team is remarkably collegiate and professional in equal measure. There is a strong alignment of mission to bring breakthrough solutions to translation and to market, addressing the unmet needs of patients in the global healthcare environment.
Board Seats (Outside Seroba’s Portfolio)
Jeanne sits on the Translation Advisory Board of the Sir Francis Crick Institute (UK), is Chair of the Board of Directors at Exevir SA (Private, Belgium), Astrivax NV (Private, Belgium), and Sapreme BV (Private, Netherlands) and Non-executive Director at Life Healthcare Group Holdings (JSE:LHC).
